Tests whether adding MRI to CT helps choose pancreatic cancer patients for surgery
Tests an MRI scan added to CT scans in adults with pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Key facts
- Where
- Aalborg, Aarhus, and Copenhagen, DenmarkSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05428358, who can take part
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus, DenmarkTaking people
- RigshospitaletCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT05428358
- Record updated
- 29 April 2026
- Original description
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.Read full original descriptionShow less
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Inclusion: Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board; No liver metastases on CT; At least 18 years old and able to provide informed consent; Expected pancreatic ductal adenocarcinoma based on CT scan.
Exclusion: Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment; Comorbidity rendering major surgery unfeasible (inoperable); Metastatic disease; Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker); No informed consent; Postoperative histology other than adenocarcinoma of pancreato-biliary origin; MRI with liver-specific contrast performed during standard workup.